About
Daniel Blessing appears to be a life sciences and medtech strategist rather than an investor. Public search evidence points to a role at ZS focused on AI strategy, growth, and digital strategy in medtech and life sciences, including in silico drug development. No credible evidence in the supplied research ties him to fund management or personal investment activity.
Areas of interest
biotechprecision medicineRNA therapeuticsgene therapyregulatory genomicsfibrosiscardiovascular diseaseheart failureage-related diseases